Peptide Research: Sermorelin – Studies, Research Use, and Scientific Background

What is Sermorelin?

Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) consisting of 29 amino acids. It is extensively studied in laboratory research for its ability to stimulate endogenous growth hormone secretion and to model growth and metabolic function in preclinical systems.
For laboratory research use only. Not for human or veterinary use.

Key Scientific Studies

• Growth Hormone Release: Studies in Journal of Clinical Endocrinology & Metabolism (1988) showed that Sermorelin administration robustly stimulates growth hormone secretion in both animal and human research models.
  Walker et al., 1988
• Metabolic and Developmental Research: Laboratory studies have used Sermorelin to model growth failure, metabolic function, and endocrine disorders in preclinical settings.
  Gaynor et al., 1991

Laboratory Research Applications

• Investigation of growth hormone axis regulation
• Preclinical models of growth and metabolic disorders
• Study of GHRH receptor signaling
• Endocrine and metabolic research

Mechanism of Action (in Research Context)

Sermorelin binds to GHRH receptors in the pituitary gland, stimulating endogenous growth hormone release. In laboratory models, it is used to assess GH axis responsiveness and to study developmental, metabolic, and endocrine pathways.

Reference Dosing Schedules from Published Studies

The following dosing protocols have been reported in published laboratory and preclinical studies of Sermorelin:

• Common Dose Range (animal studies): 20–200 mcg/kg, administered subcutaneously
• Clinical Research Dose (for reference): 0.2–0.3 mg once daily by subcutaneous injection, as reported in human research trials
• Duration: Typically 2–12 weeks, depending on experimental design